Does GlaxoSmithKline plc’s Latest Treatment Point To Its Future?

GlaxoSmithKline (LSE: GSK) has reported promising results from trials of its latest vaccine, HZ/su, which treats shingles. While it’s only one vaccine and Glaxo needs to find many more in the years to come to shore up profits, shareholders will hope it’s a small vindication of the company’s decision to double down on vaccines.

Elsewhere in the market, the Fool's experts believe sales could treble in just five years at this e-commerce stealth attack whose maverick CEO may have been underestimated by the City. For more free information on this daring buy, click here now.

Owain Bennallack owns shares in GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.